US4186745A
(en)
|
1976-07-30 |
1980-02-05 |
Kauzlarich James J |
Porous catheters
|
US4500707A
(en)
|
1980-02-29 |
1985-02-19 |
University Patents, Inc. |
Nucleosides useful in the preparation of polynucleotides
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
US5132418A
(en)
|
1980-02-29 |
1992-07-21 |
University Patents, Inc. |
Process for preparing polynucleotides
|
US4668777A
(en)
|
1981-03-27 |
1987-05-26 |
University Patents, Inc. |
Phosphoramidite nucleoside compounds
|
US4973679A
(en)
|
1981-03-27 |
1990-11-27 |
University Patents, Inc. |
Process for oligonucleo tide synthesis using phosphormidite intermediates
|
US4373071A
(en)
|
1981-04-30 |
1983-02-08 |
City Of Hope Research Institute |
Solid-phase synthesis of polynucleotides
|
US6090406A
(en)
|
1984-04-12 |
2000-07-18 |
The Liposome Company, Inc. |
Potentiation of immune responses with liposomal adjuvants
|
US4797368A
(en)
|
1985-03-15 |
1989-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adeno-associated virus as eukaryotic expression vector
|
US5153319A
(en)
|
1986-03-31 |
1992-10-06 |
University Patents, Inc. |
Process for preparing polynucleotides
|
US4853228A
(en)
|
1987-07-28 |
1989-08-01 |
Micro-Pak, Inc. |
Method of manufacturing unilamellar lipid vesicles
|
US5047524A
(en)
|
1988-12-21 |
1991-09-10 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
US5262530A
(en)
|
1988-12-21 |
1993-11-16 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
US6867195B1
(en)
|
1989-03-21 |
2005-03-15 |
Vical Incorporated |
Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
|
ES2200016T3
(es)
|
1989-03-21 |
2004-03-01 |
Vical Incorporated |
Expresion de secuencias polinucleotidicas exogenas en un vertebrado.
|
CA2017507C
(en)
|
1989-05-25 |
1996-11-12 |
Gary Van Nest |
Adjuvant formulation comprising a submicron oil droplet emulsion
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
EP0800830A3
(en)
|
1989-11-03 |
1999-03-17 |
Vanderbilt University |
Method of in vivo delivery of functioning foreign genes
|
US5674192A
(en)
|
1990-12-28 |
1997-10-07 |
Boston Scientific Corporation |
Drug delivery
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
KR100242671B1
(ko)
|
1991-03-07 |
2000-03-02 |
고돈 에릭 |
유전학적으로 처리한 백신 균주
|
FR2676072B1
(fr)
*
|
1991-05-03 |
1994-11-18 |
Transgene Sa |
Vecteur de delivrance d'arn.
|
US5750390A
(en)
|
1992-08-26 |
1998-05-12 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
|
US5693535A
(en)
|
1992-05-14 |
1997-12-02 |
Ribozyme Pharmaceuticals, Inc. |
HIV targeted ribozymes
|
US5587308A
(en)
|
1992-06-02 |
1996-12-24 |
The United States Of America As Represented By The Department Of Health & Human Services |
Modified adeno-associated virus vector capable of expression from a novel promoter
|
WO1993024640A2
(en)
|
1992-06-04 |
1993-12-09 |
The Regents Of The University Of California |
Methods and compositions for in vivo gene therapy
|
WO1994002595A1
(en)
|
1992-07-17 |
1994-02-03 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for treatment of animal diseases
|
US5474914A
(en)
|
1992-07-29 |
1995-12-12 |
Chiron Corporation |
Method of producing secreted CMV glycoprotein H
|
US20020102273A1
(en)
|
1995-08-08 |
2002-08-01 |
Robert B. Grieve |
Use of alphavirus expression vectors to produce parasite anitgens
|
EP1624068A1
(en)
|
1993-06-01 |
2006-02-08 |
Life Technologies Inc. |
Genetic immunization with cationic lipids
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
US5397307A
(en)
|
1993-12-07 |
1995-03-14 |
Schneider (Usa) Inc. |
Drug delivery PTCA catheter and method for drug delivery
|
JP3403233B2
(ja)
|
1994-01-20 |
2003-05-06 |
テルモ株式会社 |
バルーンカテーテル
|
IL112820A0
(en)
*
|
1994-03-07 |
1995-05-26 |
Merck & Co Inc |
Coordinate in vivo gene expression
|
AU2215995A
(en)
|
1994-04-07 |
1995-10-30 |
Akzo Nobel N.V. |
Freeze-dried compositions comprising rna
|
US5993850A
(en)
|
1994-09-13 |
1999-11-30 |
Skyepharma Inc. |
Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
|
US5885613A
(en)
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
DE69536153D1
(de)
|
1994-11-17 |
2011-05-05 |
Ich Productions Ltd |
Internalisierung von dna, unter verwendung von konjugaten des poly-l-lysins und eines peptidligands des integrin-rezeptors
|
AU4594996A
(en)
|
1994-11-30 |
1996-06-19 |
Chiron Viagene, Inc. |
Recombinant alphavirus vectors
|
JPH11504802A
(ja)
*
|
1994-11-30 |
1999-05-11 |
カイロン コーポレイション |
組換えアルファウイルスベクター
|
US6071890A
(en)
|
1994-12-09 |
2000-06-06 |
Genzyme Corporation |
Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
|
US5965434A
(en)
|
1994-12-29 |
1999-10-12 |
Wolff; Jon A. |
Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds
|
US5664701A
(en)
|
1995-01-25 |
1997-09-09 |
Uniplast, Inc. |
Glue gun system with removable cartridges
|
US5700642A
(en)
|
1995-05-22 |
1997-12-23 |
Sri International |
Oligonucleotide sizing using immobilized cleavable primers
|
US5792462A
(en)
|
1995-05-23 |
1998-08-11 |
University Of North Carolina At Chapel Hill |
Alphavirus RNA replicon systems
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US6264957B1
(en)
|
1995-09-27 |
2001-07-24 |
The United States Of America As Represented By The Department Of Health And Human Services |
Product of infectious respiratory syncytial virus from cloned nucleotide sequences
|
ATE455858T1
(de)
*
|
1995-11-28 |
2010-02-15 |
Univ Johns Hopkins Med |
Konditionell replizierende virale vektoren und ihre verwendung
|
DE69716240T2
(de)
|
1996-02-12 |
2003-06-26 |
Ml Lab Plc London |
Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten
|
DE19605548A1
(de)
|
1996-02-15 |
1997-09-04 |
Boehringer Ingelheim Int |
Zusammensetzung für die Transfektion höherer eukaryotischer Zellen
|
DE19612967A1
(de)
|
1996-04-01 |
1997-10-02 |
Behringwerke Ag |
Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
|
US6451592B1
(en)
|
1996-04-05 |
2002-09-17 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
CA2259179C
(en)
|
1996-07-03 |
2008-09-23 |
University Of Pittsburgh |
Emulsion formulations for hydrophilic active agents
|
US7384923B2
(en)
|
1999-05-14 |
2008-06-10 |
Lipoxen Technologies Limited |
Liposomes
|
CN1138533C
(zh)
|
1996-09-13 |
2004-02-18 |
利普森有限公司 |
脂质体
|
US6395302B1
(en)
|
1996-11-19 |
2002-05-28 |
Octoplus B.V. |
Method for the preparation of microspheres which contain colloidal systems
|
CA2289702C
(en)
|
1997-05-14 |
2008-02-19 |
Inex Pharmaceuticals Corp. |
High efficiency encapsulation of charged therapeutic agents in lipid vesicles
|
US6048546A
(en)
|
1997-07-31 |
2000-04-11 |
Sandia Corporation |
Immobilized lipid-bilayer materials
|
US6060308A
(en)
|
1997-09-04 |
2000-05-09 |
Connaught Laboratories Limited |
RNA respiratory syncytial virus vaccines
|
US6090619A
(en)
|
1997-09-08 |
2000-07-18 |
University Of Florida |
Materials and methods for intracellular delivery of biologically active molecules
|
EP0980280B1
(en)
|
1997-10-01 |
2005-02-09 |
Medtronic Ave, Inc. |
Drug delivery and gene therapy delivery system
|
JP2002500003A
(ja)
|
1997-11-28 |
2002-01-08 |
ザ・クラウン・イン・ザ・ライト・オヴ・ザ・クイーンズランド・デパートメント・オヴ・ヘルス |
フラビウイルスの発現および送達のシステム
|
US6009406A
(en)
|
1997-12-05 |
1999-12-28 |
Square D Company |
Methodology and computer-based tools for re-engineering a custom-engineered product line
|
GB9726555D0
(en)
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Vaccine
|
WO1999055310A1
(en)
|
1998-04-27 |
1999-11-04 |
Altus Biologics Inc. |
Stabilized protein crystals, formulations containing them and methods of making them
|
US6432925B1
(en)
|
1998-04-16 |
2002-08-13 |
John Wayne Cancer Institute |
RNA cancer vaccine and methods for its use
|
WO2000000616A2
(en)
|
1998-06-29 |
2000-01-06 |
U.S. Medical Research Institute Of Infectious Diseases |
Marburg virus vaccines
|
JP2002520038A
(ja)
|
1998-07-20 |
2002-07-09 |
アイネックス ファーマシューティカルズ コーポレイション |
リポソームカプセル化核酸複合体
|
WO2000039302A2
(en)
*
|
1998-12-31 |
2000-07-06 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
US6492169B1
(en)
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
EP1083232B1
(en)
|
1999-09-09 |
2005-02-23 |
CureVac GmbH |
Transfer of mRNA using polycationic compounds
|
ATE392479T1
(de)
|
1999-10-20 |
2008-05-15 |
Univ Johns Hopkins Med |
Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
|
US8541008B2
(en)
|
1999-11-19 |
2013-09-24 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Pharmaceutical compositions and methods to vaccinate against candidiasis
|
EP1103610A1
(en)
|
1999-11-26 |
2001-05-30 |
Introgene B.V. |
Production of vaccines from immortalised mammalian cell lines
|
US20030212022A1
(en)
|
2001-03-23 |
2003-11-13 |
Jean-Marie Vogel |
Compositions and methods for gene therapy
|
AU2001253323A1
(en)
|
2000-04-18 |
2001-10-30 |
Human Genome Sciences, Inc. |
Extracellular matrix polynucleotides, polypeptides, and antibodies
|
WO2001093836A2
(en)
|
2000-06-09 |
2001-12-13 |
Teni Boulikas |
Encapsulation of polynucleotides and drugs into targeted liposomes
|
DE60139690D1
(de)
|
2000-07-03 |
2009-10-08 |
Novartis Vaccines & Diagnostic |
Immunisierung gegen chlamydia pneumoniae
|
AU2001290520A1
(en)
|
2000-08-01 |
2002-02-13 |
The Johns Hokpins University |
Intercellular transport protein linked to an antigen as a molecular vaccine
|
US20040142474A1
(en)
|
2000-09-14 |
2004-07-22 |
Expression Genetics, Inc. |
Novel cationic lipopolymer as a biocompatible gene delivery agent
|
CA2421683C
(en)
|
2000-09-28 |
2009-09-15 |
Chiron Corporation |
Microparticles for delivery of the heterologous nucleic acids
|
EP1671981A3
(en)
|
2000-10-27 |
2006-07-05 |
Chiron SRL. |
Nucleic acids and proteins from streptococcus group A
|
US7445924B2
(en)
|
2000-11-23 |
2008-11-04 |
Bavarian Nordic A/S |
Modified Vaccinia Ankara virus variant and cultivation method
|
US7731975B2
(en)
|
2001-01-31 |
2010-06-08 |
The United States Of America As Represented By The Secretary Of The Army |
Chimeric filovirus glycoprotein
|
AU2002242016A1
(en)
|
2001-02-01 |
2002-08-12 |
The Johns Hopkins University |
Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
|
WO2002072027A2
(en)
|
2001-03-14 |
2002-09-19 |
University Of Alabama Research Foundation |
Oncolytic rna replicons
|
AU2002306736A1
(en)
|
2001-03-16 |
2002-10-03 |
Johns Hopkins University |
A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
|
WO2002088318A2
(en)
|
2001-04-30 |
2002-11-07 |
Targeted Genetics Corporation |
Lipid-comprising drug delivery complexes and methods for their production
|
US20030077251A1
(en)
|
2001-05-23 |
2003-04-24 |
Nicolas Escriou |
Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins
|
EP1832603B1
(de)
|
2001-06-05 |
2010-02-03 |
CureVac GmbH |
Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung
|
US20050175629A1
(en)
|
2001-08-31 |
2005-08-11 |
Giuseppe Del Giudice |
Helicobacter pylori vaccination
|
AU2002327614B2
(en)
|
2001-09-06 |
2007-12-06 |
Alphavax, Inc. |
Alphavirus replicon vector systems
|
US20050163832A1
(en)
|
2002-02-13 |
2005-07-28 |
Vladimir Torchilin |
Intracellular delivery of therapeutic agents
|
DE10207177A1
(de)
|
2002-02-19 |
2003-09-04 |
Novosom Ag |
Fakultativ kationische Lipide
|
US6861410B1
(en)
|
2002-03-21 |
2005-03-01 |
Chiron Corporation |
Immunological adjuvant compositions
|
MXPA04011249A
(es)
|
2002-05-14 |
2005-06-06 |
Chiron Srl |
Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
|
JP4722481B2
(ja)
|
2002-06-28 |
2011-07-13 |
プロティバ バイオセラピューティクス リミテッド |
リポソーム製造方法および装置
|
WO2004004758A1
(en)
|
2002-07-05 |
2004-01-15 |
Lipoxen Technologies Limited |
Method to enhance an immune response of nucleic acid vaccination
|
US20060251620A1
(en)
|
2002-08-22 |
2006-11-09 |
Lidia Ivanova |
Inducible alphaviral/orip based gene expression system
|
EA008940B1
(ru)
|
2002-09-13 |
2007-10-26 |
Репликор, Инк. |
Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
|
EP1585812B1
(en)
*
|
2002-12-13 |
2017-01-18 |
Alphavax, Inc. |
Multi-antigenic alphavirus replicon particles and methods
|
CA2508228C
(en)
|
2002-12-23 |
2013-12-17 |
Vical Incorporated |
Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
|
US8338583B2
(en)
|
2003-02-04 |
2012-12-25 |
Bar-Ilan University |
Snornai-small nucleolar RNA degradation by RNA interference in trypanosomatids
|
US20040228842A1
(en)
*
|
2003-02-27 |
2004-11-18 |
Shan Lu |
Compositions and methods for cytomegalovirus treatment
|
KR101518309B1
(ko)
|
2003-03-20 |
2015-05-08 |
알파벡스, 인크. |
개선된 알파바이러스 레플리콘 및 헬퍼 구축물
|
CA2520386A1
(en)
|
2003-03-27 |
2004-10-14 |
Children's Hospital, Inc. |
Nontypeable haemophilus influenzae virulence factors
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
EP1637144A4
(en)
|
2003-05-30 |
2010-01-13 |
Nippon Shinyaku Co Ltd |
OLIGONUCLEIC ACID CONTAINING COMPOSITE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
|
US20100255002A1
(en)
|
2003-06-26 |
2010-10-07 |
Chiron Corporation |
Immunogenic compositions for chlamydia trachomatis
|
ES2327643T3
(es)
*
|
2003-07-11 |
2009-11-02 |
Alphavax, Inc. |
Vacunas contra citomegalovirus basadas en alfavirus.
|
US7368537B2
(en)
|
2003-07-15 |
2008-05-06 |
Id Biomedical Corporation Of Quebec |
Subunit vaccine against respiratory syncytial virus infection
|
CA2532228C
(en)
|
2003-07-16 |
2017-02-14 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
PL1648500T3
(pl)
|
2003-07-31 |
2014-12-31 |
Novartis Vaccines & Diagnostics Inc |
Kompozycje immunogenne dla Streptococcus pyogenes
|
EP1512393A1
(de)
|
2003-09-08 |
2005-03-09 |
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG |
Verfahren zur Herstellung von homogenen Liposomen und Lipoplexen
|
EP1528101A1
(en)
|
2003-11-03 |
2005-05-04 |
ProBioGen AG |
Immortalized avian cell lines for virus production
|
WO2005046621A2
(en)
|
2003-11-12 |
2005-05-26 |
The United States Of America As Represented By The Secretary Of The Navy |
Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
|
US7303881B2
(en)
|
2004-04-30 |
2007-12-04 |
Pds Biotechnology Corporation |
Antigen delivery compositions and methods of use
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
JP5331340B2
(ja)
|
2004-05-18 |
2013-10-30 |
バイカル インコーポレイテッド |
インフルエンザウィルスワクチン組成物、及びその使用方法
|
WO2005113782A1
(en)
*
|
2004-05-18 |
2005-12-01 |
Alphavax, Inc. |
Tc-83-derived alphavirus vectors, particles and methods
|
GB0411428D0
(en)
|
2004-05-21 |
2004-06-23 |
Got A Gene Ab |
Vectors
|
EP2848692B1
(en)
|
2004-05-21 |
2017-08-16 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus vectors for influenza virus vaccines
|
WO2005120152A2
(en)
|
2004-06-07 |
2005-12-22 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
US7799565B2
(en)
|
2004-06-07 |
2010-09-21 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering RNA
|
AU2005327198B2
(en)
|
2004-07-09 |
2011-03-31 |
University Of North Carolina At Chapel Hill |
Viral adjuvants
|
US20060051405A1
(en)
|
2004-07-19 |
2006-03-09 |
Protiva Biotherapeutics, Inc. |
Compositions for the delivery of therapeutic agents and uses thereof
|
JP5086082B2
(ja)
|
2004-10-01 |
2012-11-28 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
C型肝炎ウイルス複製系
|
AU2005306075A1
(en)
|
2004-11-19 |
2006-05-26 |
Novosom Ag |
Improvements in or relating to pharmaceutical compositions for local administration
|
GB2421025A
(en)
|
2004-12-09 |
2006-06-14 |
Oxxon Therapeutics Ltd |
HSV vaccination vectors
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
WO2007086883A2
(en)
|
2005-02-14 |
2007-08-02 |
Sirna Therapeutics, Inc. |
Cationic lipids and formulated molecular compositions containing them
|
CA2601924A1
(en)
|
2005-02-18 |
2006-08-24 |
Novartis Vaccines And Diagnostics, Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
WO2006091517A2
(en)
|
2005-02-18 |
2006-08-31 |
Novartis Vaccines And Diagnostics Inc. |
Immunogens from uropathogenic escherichia coli
|
WO2006092607A1
(en)
|
2005-03-02 |
2006-09-08 |
The Secretary Of State For Defence |
Pharmaceutical composition
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2006110413A2
(en)
|
2005-03-30 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
Haemophilus influenzae type b
|
EP1877088B1
(en)
*
|
2005-04-11 |
2014-12-17 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Vaccine against pandemic strains of influenza viruses
|
US7618393B2
(en)
|
2005-05-03 |
2009-11-17 |
Pharmajet, Inc. |
Needle-less injector and method of fluid delivery
|
RU2007146137A
(ru)
|
2005-05-12 |
2009-06-27 |
Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) |
Иммуногенные композиции на основе chlamydia trachomatis
|
US8703095B2
(en)
|
2005-07-07 |
2014-04-22 |
Sanofi Pasteur S.A. |
Immuno-adjuvant emulsion
|
WO2007014754A1
(en)
|
2005-08-02 |
2007-02-08 |
I.D.M. Immuno-Designed Molecules |
Process for the preparation of liposomal formulations
|
US7951384B2
(en)
|
2005-08-05 |
2011-05-31 |
University Of Massachusetts |
Virus-like particles as vaccines for paramyxovirus
|
ES2937245T3
(es)
|
2005-08-23 |
2023-03-27 |
Univ Pennsylvania |
ARN que contiene nucleósidos modificados y métodos de uso del mismo
|
EP1764089A1
(en)
|
2005-09-15 |
2007-03-21 |
Novosom AG |
Serum stable liposomes comprising amphoter II lipid mixtures
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
US7511052B2
(en)
|
2005-09-29 |
2009-03-31 |
Elan Pharmaceuticals, Inc. |
Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
|
WO2007047749A1
(en)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
JP2007112768A
(ja)
|
2005-10-24 |
2007-05-10 |
Kyoto Univ |
肝指向性リポソーム組成物
|
WO2007049155A2
(en)
|
2005-10-25 |
2007-05-03 |
Novartis Vaccines And Diagnostics Srl |
Compositions comprising yersinia pestis antigens
|
CA2630220C
(en)
|
2005-11-22 |
2020-10-13 |
Doris Coit |
Norovirus and sapovirus antigens
|
JP5806444B2
(ja)
|
2005-12-02 |
2015-11-10 |
ノバルティス アーゲー |
免疫原性組成物で使用するためのナノ粒子
|
EP2004141A2
(en)
|
2006-03-17 |
2008-12-24 |
Novosom AG |
An efficient method for loading amphoteric liposomes with nucleic acid active substances
|
EP2037959B1
(en)
*
|
2006-06-07 |
2016-01-27 |
The Trustees Of Princeton University |
Cytomegalovirus surface protein complex for use in vaccines and as a drug target
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
WO2007149518A2
(en)
|
2006-06-21 |
2007-12-27 |
The Scripps Research Institute |
Dna composition against tumor stromal antigen fap and methods of use thereof
|
DK3037429T3
(en)
*
|
2006-07-28 |
2019-01-21 |
Univ Pennsylvania |
IMPROVED HIV VACCINES
|
JP2010500399A
(ja)
|
2006-08-16 |
2010-01-07 |
ノバルティス アーゲー |
尿路病原性大腸菌由来の免疫原
|
EP2061508B1
(en)
|
2006-09-12 |
2014-10-15 |
Alphavax, Inc. |
Alphavirus replicon particles matched to protein antigens as immunological adjuvants
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
JP2010519203A
(ja)
|
2007-02-16 |
2010-06-03 |
メルク・シャープ・エンド・ドーム・コーポレイション |
生物活性分子の活性を強化するための組成物及び方法
|
WO2008109806A2
(en)
|
2007-03-08 |
2008-09-12 |
Massachusetts Institute Of Technology |
Electrostatic coating of particles for drug delivery
|
US8877206B2
(en)
|
2007-03-22 |
2014-11-04 |
Pds Biotechnology Corporation |
Stimulation of an immune response by cationic lipids
|
WO2008121604A2
(en)
|
2007-03-29 |
2008-10-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the ebola
|
US8748591B2
(en)
|
2007-04-17 |
2014-06-10 |
The Board Of Regents Of The University Of Texas System |
Chimeric sindbis-western equine encephalitis virus and uses thereof
|
WO2008137758A2
(en)
|
2007-05-04 |
2008-11-13 |
Mdrna, Inc. |
Amino acid lipids and uses thereof
|
MX2009012635A
(es)
*
|
2007-05-23 |
2012-09-13 |
Mannkind Corp |
Vectores multicistronicos y metodos para su diseño.
|
DE102007029471A1
(de)
|
2007-06-20 |
2008-12-24 |
Novosom Ag |
Neue fakultativ kationische Sterole
|
CA2689588C
(en)
*
|
2007-06-21 |
2016-08-23 |
Alphavax, Inc. |
Promoterless cassettes for expression of alphavirus structural proteins
|
EP2173771A1
(en)
|
2007-07-04 |
2010-04-14 |
Ribovax Biotechnologies SA |
Antibodies against human cytomegalovirus (hcmv)
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
WO2009026328A2
(en)
|
2007-08-21 |
2009-02-26 |
Immune Disease Institute, Inc. |
Methods of delivery of agents to leukocytes and endothelial cells
|
GB0717187D0
(en)
|
2007-09-04 |
2007-10-17 |
Novartis Ag |
Compositions comprising yersinia pestis antigens
|
CA2704153A1
(en)
|
2007-09-26 |
2009-04-02 |
Vanderbilt University |
Vaccine for rsv and mpv
|
EP2042193A1
(en)
|
2007-09-28 |
2009-04-01 |
Biomay AG |
RNA Vaccines
|
US9234181B2
(en)
|
2007-11-26 |
2016-01-12 |
Novartis Ag |
RNA expression cassette and cells for making alphavirus particles
|
EP2067749A1
(en)
|
2007-11-29 |
2009-06-10 |
Total Petrochemicals France |
Process for purification of an aqueous phase containing polyaromatics
|
WO2009074861A2
(en)
|
2007-12-10 |
2009-06-18 |
Powderject Research Limited |
Improved vaccine
|
CA3044134A1
(en)
|
2008-01-02 |
2009-07-09 |
Arbutus Biopharma Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
US20110165223A1
(en)
|
2008-01-02 |
2011-07-07 |
The Johns Hopkins University |
Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen
|
ITMI20081249A1
(it)
|
2008-07-09 |
2010-01-09 |
Novartis Vaccines & Diagnostic |
Immunogeni di escherichia coli con solubilità migliorata.
|
US20110110857A1
(en)
|
2008-03-06 |
2011-05-12 |
Roberto Petracca |
Mutant forms of chlamydia htra
|
DK2279254T3
(en)
|
2008-04-15 |
2017-09-18 |
Protiva Biotherapeutics Inc |
PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
WO2009132131A1
(en)
|
2008-04-22 |
2009-10-29 |
Alnylam Pharmaceuticals, Inc. |
Amino lipid based improved lipid formulation
|
WO2009132206A1
(en)
|
2008-04-25 |
2009-10-29 |
Liquidia Technologies, Inc. |
Compositions and methods for intracellular delivery and release of cargo
|
US20100040650A1
(en)
|
2008-05-30 |
2010-02-18 |
Crowe Jr James E |
Virus-Like paramyxovirus particles and vaccines
|
EP2130912A1
(en)
|
2008-06-04 |
2009-12-09 |
Institut für Viruskrankeiten und Immunprophylaxe |
Pestivirus replicons providing an RNA-based viral vector system
|
EP2310045A1
(en)
|
2008-06-25 |
2011-04-20 |
Novartis AG |
Rapid responses to delayed booster immunisations
|
EP2310494A1
(en)
*
|
2008-06-25 |
2011-04-20 |
ProBioGen AG |
Cell line for propagation of highly attenuated alphaviruses
|
EP2960250A1
(en)
*
|
2008-07-16 |
2015-12-30 |
Institute for Research in Biomedicine |
Human cytomegalovirus neutralising antibodies and use thereof
|
JP2010025644A
(ja)
|
2008-07-16 |
2010-02-04 |
Kochi Univ Of Technology |
硝酸イオンの呈色試薬並びにこれを用いた硝酸イオンの検出及び定量方法
|
SG10201706350PA
(en)
|
2008-07-16 |
2017-09-28 |
Inst For Res In Biomedicine |
Human cytomegalovirus neutralizing antibodies and use thereof
|
WO2010017330A1
(en)
|
2008-08-06 |
2010-02-11 |
Novartis Ag |
Microparticles for use in immunogenic compositions
|
CL2008002322A1
(es)
|
2008-08-07 |
2009-06-05 |
Univ Concepcion |
Formulacion farmaceutica veterinaria que comprende un sistema vectorial viral constituido por una particula recombinante de arn que codifica una cu/zn superoxido dismutasa de la bacteria patogena de bovinos brucella abortus, y al menos un alfavirus arn perteneciente a la familia del virus semliki forest (sfv), util como vacuna.
|
EP2323628B1
(en)
|
2008-08-13 |
2022-04-13 |
California Institute of Technology |
Carrier nanoparticles and related compositions, methods and systems
|
WO2010019437A1
(en)
|
2008-08-15 |
2010-02-18 |
Novartis Ag |
Alphavirus packaging cell lines
|
US20110177122A1
(en)
|
2008-09-26 |
2011-07-21 |
The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services |
Dna prime/activated vaccine boost immunization to influenza virus
|
CN102245590B
(zh)
|
2008-10-09 |
2014-03-19 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
EP2365962B1
(en)
|
2008-11-07 |
2017-07-05 |
Massachusetts Institute of Technology |
Aminoalcohol lipidoids and uses thereof
|
MX359674B
(es)
|
2008-11-10 |
2018-10-05 |
Alnylam Pharmaceuticals Inc |
Lipidos y composiciones novedosas para el suministro de terapeuticos.
|
EP2367844A4
(en)
|
2008-11-18 |
2012-08-01 |
Ligocyte Pharmaceuticals Inc |
RSV-F VLP AND MANUFACTURING METHOD AND METHOD OF USE THEREOF
|
US20120101148A1
(en)
|
2009-01-29 |
2012-04-26 |
Alnylam Pharmaceuticals, Inc. |
lipid formulation
|
NZ612315A
(en)
|
2009-04-14 |
2014-10-31 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
JP5889783B2
(ja)
|
2009-05-05 |
2016-03-22 |
テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation |
免疫細胞へオリゴヌクレオチドを送達する方法
|
CA2764609C
(en)
|
2009-06-10 |
2018-10-02 |
Alnylam Pharmaceuticals, Inc. |
Improved cationic lipid of formula i
|
IL292615B2
(en)
|
2009-07-01 |
2023-11-01 |
Protiva Biotherapeutics Inc |
Nucleic acid-lipid particles, preparations containing them and their uses
|
EP2450031B1
(en)
|
2009-07-02 |
2018-08-29 |
Konica Minolta Holdings, Inc. |
Method for producing liposomes by two-stage emulsification method using outer aqueous phase containing specific dispersing agent, method for producing liposome dispersion or dry powder thereof using the method for producing liposomes, and liposome dispersion or dry powder thereof produced thereby
|
CA2766907A1
(en)
|
2009-07-06 |
2011-01-13 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
EP4218799A1
(en)
|
2009-07-15 |
2023-08-02 |
GlaxoSmithKline Biologicals S.A. |
Rsv f protein compositions and methods for making same
|
DK2453914T3
(en)
|
2009-07-16 |
2018-10-08 |
Vaxil Biotherapeutics Ltd |
ANTIGEN-SPECIFIC MULTIPLE PIT-BASED ANTI-INFECTIOUS VACCINES
|
EA022786B1
(ru)
|
2009-07-31 |
2016-03-31 |
Этрис Гмбх |
Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
|
ES2443952T3
(es)
|
2009-09-02 |
2014-02-21 |
Novartis Ag |
Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
|
JO3257B1
(ar)
|
2009-09-02 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات كمعدلات لفاعلية tlr
|
US20110070260A1
(en)
|
2009-09-09 |
2011-03-24 |
Baric Ralph S |
Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
|
WO2011140627A1
(en)
|
2009-11-04 |
2011-11-17 |
The University Of British Columbia |
Nucleic acid-containing lipid particles and related methods
|
US20110112353A1
(en)
|
2009-11-09 |
2011-05-12 |
Circulite, Inc. |
Bifurcated outflow cannulae
|
US20110244026A1
(en)
|
2009-12-01 |
2011-10-06 |
Braydon Charles Guild |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
US8808982B2
(en)
|
2009-12-07 |
2014-08-19 |
Cellscript, Llc |
Compositions and methods for reprogramming eukaryotic cells
|
EP3296398A1
(en)
|
2009-12-07 |
2018-03-21 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
ES2749426T3
(es)
|
2009-12-18 |
2020-03-20 |
Univ British Columbia |
Métodos y composiciones para administración de ácidos nucleicos
|
BR112012015755B1
(pt)
|
2009-12-23 |
2021-06-22 |
Novartis Ag |
Lipídeo furtivo, e composição
|
US20130101609A1
(en)
|
2010-01-24 |
2013-04-25 |
Novartis Ag |
Irradiated biodegradable polymer microparticles
|
EP2544693B1
(en)
|
2010-03-09 |
2017-09-13 |
Biomedical Research Models, Inc. |
A novel mucosal vaccination approach for herpes simplex virus type-2
|
BR112012025364A2
(pt)
|
2010-04-07 |
2015-09-22 |
Novartis Ag |
método para geração de partícula semelhante a vírus de parvovírus b19
|
ES2934240T3
(es)
|
2010-07-06 |
2023-02-20 |
Glaxosmithkline Biologicals Sa |
Partículas de administración de tipo virión para moléculas de ARN autorreplicantes
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
AU2011276234B2
(en)
*
|
2010-07-06 |
2016-02-25 |
Glaxosmithkline Biologicals S.A. |
Liposomes with lipids having an advantageous pKa- value for RNA delivery
|
PL3243526T3
(pl)
|
2010-07-06 |
2020-05-18 |
Glaxosmithkline Biologicals S.A. |
Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych
|
MX343410B
(es)
|
2010-07-06 |
2016-11-04 |
Novartis Ag * |
Emulsiones cationicas de agua en aceite.
|
CA2804492A1
(en)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Immunisation of large mammals with low doses of rna
|
MX2013000163A
(es)
|
2010-07-06 |
2013-03-05 |
Novartis Ag |
Metodos y composiciones inmunogenicas derivadas de norovirus.
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
US8898852B2
(en)
|
2010-08-04 |
2014-12-02 |
Honeywell International Inc. |
Air burst to clear detection window
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
PL4043040T3
(pl)
|
2010-08-31 |
2023-04-17 |
Glaxosmithkline Biologicals Sa |
Małe liposomy do dostarczania rna kodującego immunogen
|
JP5908477B2
(ja)
|
2010-08-31 |
2016-04-26 |
ノバルティス アーゲー |
タンパク質をコードするrnaのリポソームによる送達に適した脂質
|
RS63949B1
(sr)
|
2010-08-31 |
2023-02-28 |
Glaxosmithkline Biologicals Sa |
Pegilovani lipozomi za isporuku rnk koja kodira imunogen
|
WO2012034025A2
(en)
*
|
2010-09-09 |
2012-03-15 |
Virginia Commonwealth University |
Human cytomegalovirus vaccine
|
SG190679A1
(en)
|
2010-10-01 |
2013-07-31 |
Jason Schrum |
Engineered nucleic acids and methods of use thereof
|
TR201903651T4
(tr)
|
2010-10-11 |
2019-04-22 |
Glaxosmithkline Biologicals Sa |
Antijen uygulama platformları.
|
AU2011323844B2
(en)
|
2010-10-25 |
2016-09-08 |
Stepan Company |
Quaternized fatty amines, amidoamines, and their derivatives from natural oil metathesis
|
US9405700B2
(en)
|
2010-11-04 |
2016-08-02 |
Sonics, Inc. |
Methods and apparatus for virtualization in an integrated circuit
|
EP2667892B1
(en)
|
2011-01-26 |
2019-03-27 |
GlaxoSmithKline Biologicals SA |
Rsv immunization regimen
|
WO2012106377A2
(en)
|
2011-01-31 |
2012-08-09 |
The Trustees Of The University Of Pennsylvania |
Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
PT2707385T
(pt)
|
2011-05-13 |
2017-12-19 |
Glaxosmithkline Biologicals Sa |
Antigénios de f de rsv pré-fusão
|
WO2012158736A1
(en)
|
2011-05-17 |
2012-11-22 |
modeRNA Therapeutics |
Engineered nucleic acids and methods of use thereof for non-human vertebrates
|
EP4212514A1
(en)
|
2011-06-08 |
2023-07-19 |
Translate Bio, Inc. |
Cleavable lipids
|
US11058762B2
(en)
|
2011-07-06 |
2021-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
JP2014520806A
(ja)
|
2011-07-06 |
2014-08-25 |
ノバルティス アーゲー |
Rna分子の送達のための有用なn:p比を有するリポソーム
|
EP3332802A1
(en)
|
2011-07-06 |
2018-06-13 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
CN103781470A
(zh)
|
2011-07-06 |
2014-05-07 |
诺华股份有限公司 |
包含核酸的水包油乳液
|
CN103796639B
(zh)
|
2011-07-06 |
2017-05-31 |
诺华股份有限公司 |
阳离子水包油乳液
|
LT2750707T
(lt)
|
2011-08-31 |
2019-01-10 |
Glaxosmithkline Biologicals Sa |
Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
|
EP3384938A1
(en)
|
2011-09-12 |
2018-10-10 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
SG11201401196WA
(en)
|
2011-10-03 |
2014-05-29 |
Moderna Therapeutics Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
MX2014004214A
(es)
|
2011-10-11 |
2014-05-07 |
Novartis Ag |
Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
|
WO2013054199A2
(en)
|
2011-10-12 |
2013-04-18 |
Novartis Ag |
Cmv antigens and uses thereof
|
EP2791364A4
(en)
|
2011-12-14 |
2015-11-11 |
Moderna Therapeutics Inc |
METHODS OF RESPONSE TO A BIOLOGICAL THREAT
|
AU2012352180A1
(en)
|
2011-12-16 |
2014-07-31 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
CN104968354A
(zh)
|
2011-12-21 |
2015-10-07 |
现代治疗公司 |
增加器官或器官外植体的活力或寿命的方法
|
CA2868391A1
(en)
|
2012-04-02 |
2013-10-10 |
Stephane Bancel |
Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
|
US9192651B2
(en)
|
2012-04-02 |
2015-11-24 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of secreted proteins
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
CN109045294A
(zh)
|
2013-01-10 |
2018-12-21 |
思齐乐 |
流感病毒免疫原性组合物及其应用
|
US9504747B2
(en)
|
2013-03-08 |
2016-11-29 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
US20160032316A1
(en)
|
2013-03-14 |
2016-02-04 |
The Trustees Of The University Of Pennsylvania |
Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
US10059655B2
(en)
|
2013-12-19 |
2018-08-28 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
RS63030B1
(sr)
|
2015-09-17 |
2022-04-29 |
Modernatx Inc |
Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
|
HUE061564T2
(hu)
|
2015-10-28 |
2023-07-28 |
Acuitas Therapeutics Inc |
Új lipidek és lipid nanorészecske készítmények nukleinsavak bevitelére
|
CA3043033A1
(en)
|
2016-11-10 |
2018-05-17 |
Translate Bio, Inc. |
Improved ice-based lipid nanoparticle formulation for delivery of mrna
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
AU2019384557A1
(en)
|
2018-11-21 |
2021-06-10 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
|
EP4021407A1
(en)
|
2019-08-30 |
2022-07-06 |
GlaxoSmithKline Biologicals S.A. |
Jet mixing lipid nanoparticle manufacturing process
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|